Nicotine_Patches: profile and news
Tibotec Announces FDA Acceptance for Review of NDA for TMC114 07 Mar 2006
Phase III clinical trials of TMC114, boosted with low-dose ritonavir, are currently ongoing in both treatment-experienced and treatment-naive HIV-1 infected ... - Yahoo! News (press release)
CROI: Studies look at tipranavir/ritonavir's potency and ... Feb 28, 2006
...presented to the recent Conference on Opportunistic Infections and Retroviruses (CROI) on the recently approved protease inhibitor tipranavir/ritonavir (Aptivus ... - Aidsmap,
CROI: Atazanavir and atazanavir/ritonavir safe and effective in ... Feb 13, 2006
Atazanavir (Reyataz) boosted by ritonavir has a potent anti-HIV effect and is generally well tolerated when used to treat individuals who have never taken anti ... - Aidsmap,
CROI: atazanavir/ritonavir joins other boosted PIs as potential ... Feb 8, 2006
Atazanavir/ritonavir appears to have similar effectiveness to lopinavir/ritonavir or saquinavir/ritonavir when used as a maintenance regimen in patients who ... - Aidsmap,
Atazanvir/Ritonavir Monotherapy Maintains Viral Suppression in ... Feb 8, 2006
CO -- February 8, 2006 -- Results of a small pilot study show that patients infected with HIV maintained viral suppression with atazanavir/ritonavir for at ... - DG News
Roche to Focus Resources on Availability of Invirase, Now ... Feb 6, 2006
The Invirase 500 mg tablet formulation requires only four tablets daily – two in the morning and two in the evening, taken with ritonavir. ... - DG News
New 48 Week Clinical Trial Data Reported Comparing REYATAZ(R) ... Feb 9, 2006
...response and the safety profile of the once-daily protease inhibitor REYATAZ(R) (atazanavir sulfate), both with or without low-dose ritonavir, as part of ... - Finanzen.net,
CROI: Saquinavir-based combination prevents mother-to-child HIV ... Feb 22, 2006
Short-term anti-HIV drug combinations including ritonavir (Norvir)-boosted saquinavir (Invirase) are more effective at reducing viral loads in the third ... - Aidsmap,
Boehringer Ingelheim Announces 48-week Results from Aptivus(R) ... Feb 9, 2006
The RESIST trials are randomized, controlled, open-label Phase 3 trials designed to study APTIVUS combined with ritonavir (APTIVUS/r) versus a group of ... - PR Newswire (press release),
Pharmacokinetics Study Suggest No Problems in Combining Lopinavir ... Feb 10, 2006
..."The combination of lopinavir/ritonavir and atazanavir with nucleoside ... In period 1 (days 1-10), atazanavir/ritonavir 300/100 mg was administered once daily. ... - DG News
CROI: Do boosted protease inhibitors have a lower risk of ... Feb 23, 2006
Anti-HIV treatment regimens including ritonavir (Norvir)-boosted protease inhibitors may be more forgiving of low adherence than those including unboosted ... - Aidsmap,
Steroids with Protease Inhibitors May Increase the Risk of Bone ... Feb 3, 2006
15 issue of the "Journal of Acquired Immune Deficiency Syndrome", the study showed that ritonavir, a protease inhibitor used to treat HIV patients, taken with ... - Kansas City infoZine,
Advances in First-Line and "Switch" Antiretroviral Strategies for ... Feb 2, 2006
...either a nonnucleoside analogue reverse transcriptase inhibitor (NNRTI) or a protease inhibitor (PI) with or without pharmacokinetic enhancement with ritonavir ... - Medscape (subscription)
Bristol Myers Squibb announces voluntary licenses for atazanavir ... Feb 15, 2006
...treatments available in resource-limited settings, but atazanavir use may be limited by the lack of access to the boosting agent ritonavir, another protease ... - Aidsmap,
Positive results for a novel oral HIV integrase inhibitor Feb 10, 2006
...load among HIV-positive patients receiving GS 9137, or JTK-303, a novel oral HIV integrase inhibitor, as monotherapy or in combination with ritonavir as a ... - Xagena.it,
Update 2: Today in History - March 1 Feb 28, 2006
The Food and Drug Administration approved a powerful new AIDS drug, saying ritonavir could prolong slightly the lives of severely ill patients. ... - Forbes
CROI: Studies begin to identify genes linked to metabolic and body ... Feb 26, 2006
...apolipoprotein genes, two in gene E, three in gene C and one in gene A. In a cohort of 370 patients enrolled in a trial comparing ritonavir-boosted lopinavir ... - Aidsmap,
CROI: Low rates of resistance seen in Staccato trial of CD4-guided ... Feb 26, 2006
Overall, 80% of the patients in Staccato took ritonavir (Norvir)-boosted saquinavir (Invirase) along with two nucleoside reverse transcriptase inhibitors (NRTIs ... - Aidsmap,
Today in History, March 1 Mar 1, 2006
1996: The Food and Drug Administration approved a powerful new AIDS drug, saying ritonavir could prolong slightly the lives of severely ill patients. - The State,
Restoration of CD4 T-cells limited in children starting HIV ... Mar 2, 2006
...lamivudine, Epivir). The protease inhibitors taken by most children were nelfinavir (Viracept) and ritonavir (Norvir). Although ... - Aidsmap,
Early Results Show Efficacy With Gilead Integrase Inhibitor ... Feb 9, 2006
...dosing regimens in the trial -- 200 mg twice a day, 400 mg twice a day, 800 mg twice a day, 800 mg once a day or 50 mg boosted by 100 mg ritonavir once a day. ... - DG News
Boehringer Ingelheim Announces 48-week Results from Aptivus ... Feb 10, 2006
The RESIST trials are randomized, controlled, open-label Phase 3 trials designed to study Aptivus combined with ritonavir (Aptivus/r) versus a group of ... - DG News
CROI: etravirine (TMC125) and darunavir (TMC114) in treatment ... Feb 13, 2006
They were randomly assigned to receive one of four doses of darunavir boosted with ritonavir (Norvir) or else a comparator PI selected by the investigators. ... - Aidsmap,
Panacos Reports Fourth Quarter and Full Year Results for 2005 ... Feb 14, 2006
Completed dosing in most subjects in a drug interaction trial studying the possible effects of co-administration of PA-457 with the approved HIV drug ritonavir ... - Genetic Engineering News,
Schering-Plough Presents Vicriviroc Clinical Study Results at 13th ... Feb 10, 2006
The results of drug interaction studies with vicriviroc and ritonavir- boosted protease inhibitors was the subject of another presentation by Schering-Plough ... - DG News
Schering-Plough Presents Vicriviroc Clinical Study Results at 13th ... Feb 10, 2006
Drug Interaction Studies The results of drug interaction studies with vicriviroc and ritonavir- boosted protease inhibitors was the subject of another ... - PR Newswire (press release),
Bristol-Myers Allows Powerful AIDS Drug to Be Sold Cheaply Feb 14, 2006
Guidelines from the World Health Organization require that protease inhibitors be given with what is called a booster drug — usually ritonavir, sold under ... - New York Times,
CROI: New Integrase Drugs Take Aim at Essential HIV Target Feb 10, 2006
Patients received 200 mg, 400 mg or 800 mg twice a day, or r 800 mg once a day, or 50 mg boosted by 100 mg of ritonavir. He noted ... - CNN
Bristol-Myers Squibb To License Antiretroviral Reyataz to Generic ... Feb 15, 2006
Under World Health Organization guidelines, atazanavir is best taken with a booster drug, usually Abbott Laboratories' ritonavir, according to the New York ... - Kaiser network.org,
New Data on Tibotec HIV/AIDS Investigational Product Portfolio Feb 16, 2006
In addition to TMC125 and TMC114 boosted with low-dose ritonavir, patients received two or more NRTIs; two patients used enfuvirtide for the first time. ... - PharmaLive.com (press release),
Gilead Announces Results from Phase I/II Study of Investigational ... Feb 9, 2006
Breaker #160LB), show significant reductions in viral load among HIV-positive patients receiving GS 9137 as monotherapy or in combination with ritonavir as a ... - Genetic Engineering News,
US, Brazil Dispute Patent Protection Feb 24, 2006
...minister of health began proceedings to issue a compulsory license for the production of three antiretroviral medications: Lopinavir/Ritonavir, Efavirenz, and ... - The Heartland Institute,
CROI: New Gilead integrase inhibitor GS-9137 displays potent ... Feb 8, 2006
...and non-nucleoside reverse transcriptase inhibitors are expected, but drug levels are boosted 20-fold when dosed with 100mg of ritonavir, allowing once daily ... - Aidsmap,
CROI: AZT, 3TC and FTC achieve good concentrations in the female ... Feb 17, 2006
...regimens that included 3TC, AZT, abacavir (Ziagen), ddI (didanosine, Videx), d4T (stavudine, Zerit), efavirenz (Sustiva), lopinavir/ritonavir (Kaletra) and ... - Aidsmap,
CROI: Study reveals widespread misunderstandings about post ... Feb 10, 2006
The regimens compared were AZT/3TC (Combivir) plus nelfinavir; Combivir plus lopinavir/ritonavir (Kaletra); Combivir plus tenofovir; and tenofovir/3TC plus ... - Aidsmap,
Multi-component drug delivery system: An emerging trend Feb 8, 2006
Inhibitors (PIs), which include amprenavir (Agenerase), nelfinavir (Viracept), saquinavir (Fortavase), indinavir (Crixivan), ritonavir (Norvir), saquinavir ... - Express Pharma Pulse,
India, Africa get free HIV drug license Feb 15, 2006
...clear how much impact the licensing will have, however, because Reyataz is typically used in conjunction with Abbott Laboratories' ritonavir, which requires ... - United Press International
CROI: Treatment Interruptions Prove Dismal News for HIV Patients Feb 8, 2006
...taking the nucleoside reverse transcriptase backbone of the regimen, but remained on the protease inhibitor Reyataz (atazanavir), boosted by Norvir (ritonavir ... - MedPage Today,
CROI: Tenofovir and kidney toxicity - low rates seen, but some ... Feb 9, 2006
...chance of renal decline. So did patients taking lopinavir/ritonavir, according to one measurement method used. And so did patients ... - Aidsmap,
Impaired Glucose Tolerance Frequent Among HIV-Infected Pregnant ... Feb 10, 2006
The women in the study were most frequently using nelfinavir and lopinavir/ritonavir as their protease inhibitor; nevirapine was the most frequent non-protease ... - DG News
Merck Announces Interim Results from Phase II Study of MK-0518, an ... Feb 9, 2006
...evaluation was determined to have no genotoxicity in vitro or in vivo, is not a potent inhibitor or inducer of CYP3A4 (does not require ritonavir boosting) and ... - Genetic Engineering News,
CROI: Heart attack risk elevated by protease inhibitor treatment ... Feb 8, 2006
...alone, the investigators did find a trend towards a more rapid increase in artery wall thickening in three groups: patients taking ritonavir (Norvir), patients ... - Aidsmap,
(PRN) - Specialty Metals Industry Group Releases Eleven-Month ... Feb 9, 2006
...[+]. (PRN) - New 48 Week Clinical Trial Data Reported Comparing REYATAZ(R) (Atazanavir Sulfate), With or Without Ritonavir, in Treatment-Naive Patients ... [+. ... - Bolsamania.com,
Roche To Stop Selling Protease Inhibitor Fortovase Because of ... Feb 8, 2006
...plans to discontinue the drug ( Reuters , 2/6). FDA in December 2004 approved 500 mg Invirase tablets, which are taken twice daily with 100 mg ritonavir as a ... - Kaiser network.org,
Positive Pre-Clinical Data on Two New Investigational HIV Fusion ... Feb 9, 2006
Antiretroviral Treatment Guidelines from the US Department of Health and Human Services (DHHS) established the use of FUZEON and an active ritonavir-boosted PI ... - PR Newswire (press release),
Management of HIV/HBV Coinfection Feb 8, 2006
...management plan was developed and the patient initiated therapy with the fixed-dose combination of tenofovir and emtricitabine and ritonavir-boosted atazanavir ... - Medscape (subscription)
